Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Pieris Pharmaceuticals
Pieris Pharmaceuticals
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Media
Merck is set to lead pharmaceutical licensing deals in 2018
GlobalData, a specialist data and analytics company, expects that 2018 is likely to be Merck’s year in terms of research and development collaboration
Media
Pieris Pharmaceuticals appoints new Chairman for Board of Directors
Pharmaceutical
Pieris Pharmaceuticals appoints James Geraghty to its Board of Directors
Regulatory
Commercialised anticalin inhaled treatments
Pieris Pharmaceuticals and AstraZeneca collaborate to develop and commercialise treatments for respiratory diseases
Ingredients
Pieris announces first cancer immunotherapy collaboration
Agreement with Roche leverages proprietary Anticalin technology platform
Pharmaceutical
Pieris Pharmaceuticals appoints Chief Development Officer
Louis Matis takes up the position at the biotechnology company
Research & Development
Pieris Pharmaceuticals and the University of Melbourne receive grant
To advance Anticalin-based therapeutic for inhaled delivery to treat asthmatics
Subscribe now